Analyst Ratings for Regeneron Pharma (REGN) [Buys]
REGN Rating Summary
REGN Price Target Summary
- Highest: $315.00 (Brean Capital)
- Lowest: $60.00 (Needham & Company)
- Average: $163.53
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$163.53 (-35.8%)
Avg. $ Target:
$163.53 (-35.8%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/3/2013 | Brean Capital | Upgrade | Buy (Hold) |
315.00 (N/A) |
248.63 | 254.87 | 2.51% | Details |
| 5/2/2013 | JMP Securities | Upgrade | Market Outperform (Market Perform) |
N/A (N/A) |
237.29 | 254.87 | 7.41% | Details |
| 2/28/2013 | Barclays | New Coverage | Overweight (N/A) |
194.00 (N/A) |
164.80 | 254.87 | 54.65% | Details |
| 11/13/2012 | Credit Suisse | New Coverage | Outperform (N/A) |
187.00 (N/A) |
144.90 | 254.87 | 75.89% | Details |
| 7/25/2012 | BMO Capital | Upgrade | Outperform (Market Perform) |
158.00 (143.00) |
121.44 | 254.87 | 109.87% | Details |
| 4/2/2012 | Goldman Sachs » Updated 4/9/2013 |
New Coverage | Buy (N/A) |
215.00 (196.00) |
116.62 | 254.87 | 118.55% | Details |
| 2/3/2012 | ThinkEquity | New Coverage | Buy (N/A) |
120.00 (N/A) |
95.01 | 254.87 | 168.26% | Details |
| 1/30/2012 | BofA/Merrill Lynch | Upgrade | Buy (N/A) |
N/A (N/A) |
85.54 | 254.87 | 197.95% | Details |
| 1/10/2012 | Baird » Updated 1/15/2013 |
Upgrade | Outperform (N/A) |
205.00 (176.00) |
65.48 | 254.87 | 289.23% | Details |
| 10/26/2011 | Leerink Swann » Updated 4/3/2013 |
Upgrade | Outperform (N/A) |
190.00 (185.00) |
57.09 | 254.87 | 346.44% | Details |
| 7/28/2011 | RBC Capital » Updated 1/3/2012 |
Upgrade | Outperform (N/A) |
70.00 (N/A) |
52.65 | 254.87 | 384.08% | Details |
| 4/13/2011 | Deutsche Bank » Updated 5/1/2013 |
New Coverage | Buy (N/A) |
310.00 (275.00) |
42.85 | 254.87 | 494.8% | Details |
